这项研究由美国国立卫生研究院(National Institutes of Health)和德国政府(一部分共同作者在波恩大学[University of Bonn]工作)资助。东北大学对这种生产药物的方法持有专利并将其授权给了一家私营公司NovoBiotic Pharmaceuticals(位于马萨诸塞州剑桥市),该公司对使用该方法生产的任何化合物持所有权。刘易斯博士是该公司的有酬顾问。
Teixobactin is the most promising candidate isolated from 10,000 strains of bacteria that the researchers screened. In test tubes, it killed various types of staph and strep, as well as anthrax and tuberculosis. Tested in mice, it cleared strep infections and staph, including a strain that was drug-resistant. It works against bacteria in a group known as “Gram-positive,” but not against microbes that are “Gram-negative,” which include some that are major causes of drug resistant pneumonia, gonorrhea and infections of the bladder and bloodstream. Dr. Lewis said researchers were trying to modify the drug to make it work against Gram-negative infections.
Teixobactin是研究人员从10000株细菌菌株中筛选分离出来的最有前途的候选药物。在试管中,它可以杀死多种类型的葡萄球菌和链球菌,以及炭疽和结核病的病原体。在小鼠身上测试时,它可以清除链球菌感染和葡萄球菌,其中也包括耐药菌株。它可以作用于一类被称为“革兰氏阳性”的细菌,但对“革兰氏阴性”细菌(如耐药性肺炎、淋病、膀胱和血液感染的某些主要致病菌)无效。刘易斯博士表示,研究人员正试图对该药物进行改良,希望它也可以用来治疗革兰氏阴性菌感染。
【关于抗生素的一条好消息】相关文章:
最新
2020-09-15
2020-09-15
2020-09-15
2020-09-15
2020-09-15
2020-09-15